Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 07 01 2019
revised: 04 12 2019
accepted: 06 01 2020
pubmed: 18 3 2020
medline: 7 7 2020
entrez: 18 3 2020
Statut: ppublish

Résumé

The clinical syndromes of frontotemporal dementia are clinically and neuropathologically heterogeneous, but processes such as neuroinflammation may be common across the disease spectrum. We investigated how neuroinflammation relates to the localization of tau and TDP-43 pathology, and to the heterogeneity of clinical disease. We used PET in vivo with (i) 11C-PK-11195, a marker of activated microglia and a proxy index of neuroinflammation; and (ii) 18F-AV-1451, a radioligand with increased binding to pathologically affected regions in tauopathies and TDP-43-related disease, and which is used as a surrogate marker of non-amyloid-β protein aggregation. We assessed 31 patients with frontotemporal dementia (10 with behavioural variant, 11 with the semantic variant and 10 with the non-fluent variant), 28 of whom underwent both 18F-AV-1451 and 11C-PK-11195 PET, and matched control subjects (14 for 18F-AV-1451 and 15 for 11C-PK-11195). We used a univariate region of interest analysis, a paired correlation analysis of the regional relationship between binding distributions of the two ligands, a principal component analysis of the spatial distributions of binding, and a multivariate analysis of the distribution of binding that explicitly controls for individual differences in ligand affinity for TDP-43 and different tau isoforms. We found significant group-wise differences in 11C-PK-11195 binding between each patient group and controls in frontotemporal regions, in both a regions-of-interest analysis and in the comparison of principal spatial components of binding. 18F-AV-1451 binding was increased in semantic variant primary progressive aphasia compared to controls in the temporal regions, and both semantic variant primary progressive aphasia and behavioural variant frontotemporal dementia differed from controls in the expression of principal spatial components of binding, across temporal and frontotemporal cortex, respectively. There was a strong positive correlation between 11C-PK-11195 and 18F-AV-1451 uptake in all disease groups, across widespread cortical regions. We confirmed this association with post-mortem quantification in 12 brains, demonstrating strong associations between the regional densities of microglia and neuropathology in FTLD-TDP (A), FTLD-TDP (C), and FTLD-Pick's. This was driven by amoeboid (activated) microglia, with no change in the density of ramified (sessile) microglia. The multivariate distribution of 11C-PK-11195 binding related better to clinical heterogeneity than did 18F-AV-1451: distinct spatial modes of neuroinflammation were associated with different frontotemporal dementia syndromes and supported accurate classification of participants. These in vivo findings indicate a close association between neuroinflammation and protein aggregation in frontotemporal dementia. The inflammatory component may be important in shaping the clinical and neuropathological patterns of the diverse clinical syndromes of frontotemporal dementia.

Identifiants

pubmed: 32179883
pii: 5803192
doi: 10.1093/brain/awaa033
pmc: PMC7089669
doi:

Substances chimiques

Carbolines 0
Carbon Radioisotopes 0
DNA-Binding Proteins 0
Isoquinolines 0
Protein Aggregates 0
TARDBP protein, human 0
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole J09QS3Z3WB
PK 11195 YNF83VN1RL

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1010-1026

Subventions

Organisme : Medical Research Council
ID : MR/P01271X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M009041/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 103838
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M024873/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 103838
Pays : United Kingdom

Informations de copyright

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

Front Syst Neurosci. 2008 Nov 24;2:4
pubmed: 19104670
J Alzheimers Dis. 2013;34(2):457-68
pubmed: 23234879
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
PLoS Med. 2018 Jan 9;15(1):e1002487
pubmed: 29315334
Neuroscientist. 2015 Apr;21(2):169-84
pubmed: 24722525
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1107-11
pubmed: 15258209
JAMA Neurol. 2013 Jan;70(1):78-84
pubmed: 23318515
J Alzheimers Dis. 2012;31(3):601-12
pubmed: 22683529
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1024-1031
pubmed: 28986472
J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):956-62
pubmed: 23543794
Neuron. 2010 Oct 6;68(1):19-31
pubmed: 20920788
Alzheimers Dement. 2015 Sep;11(9):1110-20
pubmed: 25449529
Brain. 2016 Sep;139(Pt 9):2372-9
pubmed: 27357347
Alzheimers Dement. 2013 Nov;9(6):666-76
pubmed: 23411393
Am J Pathol. 2011 Jan;178(1):284-95
pubmed: 21224065
J Comp Neurol. 2010 Oct 1;518(19):3931-47
pubmed: 20737593
Nature. 2017 Jan 26;541(7638):481-487
pubmed: 28099414
ACS Chem Neurosci. 2019 Aug 21;10(8):3839-3846
pubmed: 31339297
Neurology. 2018 May 29;90(22):e1989-e1996
pubmed: 29703774
J Exp Med. 2010 Jan 18;207(1):117-28
pubmed: 20026663
J Neurol Neurosurg Psychiatry. 2011 May;82(5):476-86
pubmed: 20971753
Ann Clin Transl Neurol. 2018 Sep 14;5(10):1292-1296
pubmed: 30349864
Am J Pathol. 2016 Feb;186(2):375-84
pubmed: 26687817
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1032-1037
pubmed: 28912300
J Nucl Med. 2007 Jan;48(1):158-67
pubmed: 17204713
J Neuropathol Exp Neurol. 2008 Oct;67(10):1001-10
pubmed: 18800007
BMJ Open. 2017 Jan 7;7(1):e013187
pubmed: 28064175
Sci Rep. 2018 Mar 16;8(1):4717
pubmed: 29549278
J Neuroinflammation. 2015 May 29;12:108
pubmed: 26022249
Acta Neuropathol Commun. 2016 Jun 13;4(1):58
pubmed: 27296779
J Neurosci. 2011 Mar 2;31(9):3344-50
pubmed: 21368046
Mol Imaging Biol. 2018 Jun;20(3):356-360
pubmed: 29127552
Ann Neurol. 2015 Nov;78(5):787-800
pubmed: 26344059
Neurobiol Aging. 2013 Aug;34(8):2077.e11-8
pubmed: 23582655
Ann Neurol. 2004 Dec;56(6):894-7
pubmed: 15562429
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Annu Rev Immunol. 2014;32:367-402
pubmed: 24471431
Parkinsonism Relat Disord. 2010 Jul;16(6):404-8
pubmed: 20452812
Ann Neurol. 2017 Mar;81(3):430-443
pubmed: 28133816
Neurology. 2018 Mar 13;90(11):e947-e954
pubmed: 29440563
J Nucl Med. 2019 Oct;60(10):1444-1451
pubmed: 30877180
Mol Imaging Biol. 2005 Nov-Dec;7(6):377-87
pubmed: 16265597
Ann Clin Transl Neurol. 2019 Jan 02;6(2):373-378
pubmed: 30847369
Curr Neurol Neurosci Rep. 2015 Apr;15(4):17
pubmed: 25716012
Nat Rev Immunol. 2014 Jul;14(7):463-77
pubmed: 24962261
J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):21-8
pubmed: 26384512
Mol Neurodegener. 2013 Jun 21;8:19
pubmed: 23800361
Alzheimers Res Ther. 2018 Aug 16;10(1):79
pubmed: 30111356
Ann Clin Transl Neurol. 2016 Oct 18;3(12):940-947
pubmed: 28097206
Alzheimers Dement. 2016 Nov;12(11):1116-1124
pubmed: 26892233
J Biochem. 2001 Aug;130(2):169-75
pubmed: 11481032
Neuropathol Appl Neurobiol. 2014 Oct;40(6):686-96
pubmed: 24117616
J Pharmacol Exp Ther. 1981 Jan;216(1):183-91
pubmed: 6256524
Neuropsychopharmacology. 2013 May;38(6):938-49
pubmed: 23303049
Glia. 2002 Nov;40(2):206-17
pubmed: 12379908
Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e301
pubmed: 27844039
Acta Neuropathol. 2010 Jan;119(1):1-4
pubmed: 19924424
Science. 2016 Mar 18;351(6279):1324-9
pubmed: 26989253
Neuron. 2007 Feb 1;53(3):337-51
pubmed: 17270732
Neurology. 2017 Aug 22;89(8):845-853
pubmed: 28754841
Mov Disord. 2018 Feb;33(2):273-281
pubmed: 29278274
J Cereb Blood Flow Metab. 2012 Aug;32(8):1600-8
pubmed: 22588187
Acta Neuropathol. 2016 Dec;132(6):935-937
pubmed: 27815633
Brain. 2018 Sep 1;141(9):2740-2754
pubmed: 30052812

Auteurs

W Richard Bevan-Jones (WR)

Department of Psychiatry, University of Cambridge, Cambridge, UK.

Thomas E Cope (TE)

Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.

P Simon Jones (PS)

Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Sanne S Kaalund (SS)

Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Luca Passamonti (L)

Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Istituto di Bioimmagini e Fisiologia Molecolare (IBFM), Consiglio Nazionale delle Ricerche (CNR), via Fratelli Cervi, Milano, Italy.

Kieren Allinson (K)

Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridge, UK.

Oliver Green (O)

Istituto di Bioimmagini e Fisiologia Molecolare (IBFM), Consiglio Nazionale delle Ricerche (CNR), via Fratelli Cervi, Milano, Italy.

Young T Hong (YT)

Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.

Tim D Fryer (TD)

Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.

Robert Arnold (R)

Department of Psychiatry, University of Cambridge, Cambridge, UK.

Jonathan P Coles (JP)

Division of Anaesthesia, University of Cambridge, UK.

Franklin I Aigbirhio (FI)

Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.

Andrew J Larner (AJ)

Department of Neurology, The Walton Centre, Liverpool, UK.

Karalyn Patterson (K)

Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.

John T O'Brien (JT)

Department of Psychiatry, University of Cambridge, Cambridge, UK.

James B Rowe (JB)

Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH